Characterization of CM572, a selective irreversible partial agonist of the sigma-2 receptor with antitumor activity

Journal of Pharmacology and Experimental Therapeutics

Volumn 354, Issue 2, 2015, Pages 203-212

  Nicholson, Hilary ^a   Comeau, Anthony ^a   Mesangeau, Christophe ^b   McCurdy, Christopher R ^b   Bowen, Wayne D ^a  

^a BROWN UNIVERSITY   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 1 (6 CHLORO 2 PYRIDYL)PIPERIDINE; SIGMA 2 OPIATE RECEPTOR; ANTINEOPLASTIC AGENT; BENZOXAZOLE DERIVATIVE; CM572 COMPOUND; ISOCYANIC ACID DERIVATIVE; NARCOTIC ANALGESIC AGENT; PROTEIN BINDING; SIGMA OPIATE RECEPTOR; SIGMA-2 RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING ASSAY; BREAST CANCER; BREAST EPITHELIUM CELL; CANCER CELL; CELL DEATH; CELL VIABILITY; CONCENTRATION RESPONSE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SELECTIVITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; LIGAND BINDING; LIVER MEMBRANE; MELANOCYTE; NEUROBLASTOMA CELL; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; AGONISTS; ANIMAL; CHEMISTRY; DOSE RESPONSE; MCF 7 CELL LINE; METABOLISM; PARTIAL AGONISM; PHYSIOLOGY; TUMOR CELL LINE;

ANALGESICS, OPIOID; ANIMALS; ANTINEOPLASTIC AGENTS; BENZOXAZOLES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG PARTIAL AGONISM; HUMANS; ISOCYANATES; MCF-7 CELLS; PROTEIN BINDING; RATS; RECEPTORS, SIGMA;

EID: 84941564384     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.115.224105     Document Type: Article

References (31)

1. Abate C, Perrone R, and Berardi F (2012) Classes of sigma2 (s2) receptor ligands: structure affinity relationship (SAfiR) studies and antiproliferative activity. Curr Pharm Des 18:938-949.
2. Al-Nabulsi I, Mach RH, Wang LM, Wallen CA, Keng PC, Sten K, Childers SR, and Wheeler KT (1999) Effect of ploidy, recruitment, environmental factors, and tamoxifen treatment on the expression of sigma-2 receptors in proliferating and quiescent tumour cells. Br J Cancer 81:925-933.
3. Bowen WD (2007) Sigma-2 receptors: regulation of cell growth and implications for cancer diagnosis and therapeutics, in Sigma Receptors: Chemistry, Cell Biology and Clinical Implications (Mastumoto R, Su TP, and Bowen WD eds) pp 215-235, Springer, New York.
4. Bowen WD, Bertha CM, Vilner BJ, and Rice KC (1995) CB-64D and CB-184: ligands with high sigma 2 receptor affinity and subtype selectivity. Eur J Pharmacol 278:257-260.
5. Cassano G, Gasparre G, Niso M, Contino M, Scalera V, and Colabufo NA (2009) F281, synthetic agonist of the sigma-2 receptor, induces Ca2+ efflux from the endoplasmic reticulum and mitochondria in SK-N-SH cells. Cell Calcium 45:340-345.
6. Cesen MH, Repnik U, Turk V, and Turk B (2013) Siramesine triggers cell death through destabilisation of mitochondria, but not lysosomes. Cell Death Dis 4:e818.
7. Comeau A, Mesangeau C, McCurdy CR, and Bowen WD (2012) Development of selective irreversible affinity ligands for sigma-2 receptors. Neuroscience 2012; 2012 Oct 13-17; New Orleans, LA.
8. Crawford KW and Bowen WD (2002) Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines. Cancer Res 62:313-322.
9. Garcia DR (2012) Sigma-2 Receptor-Mediated Cytotoxicity and Calcium Signaling: Evidence for Bifurcating Pathways. Doctoral thesis, Brown University, Providence, RI.
10. Hayashi T and Su TP (2007) Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. Cell 131:596-610.
11. Hazelwood S and Bowen WD (2006) Sigma-2 receptor-mediated apoptosis in human SK-N-SH neuroblastoma cells: role of lipid rafts, caspases, and mitochondrial depolarization. Proc Am Assoc Cancer Res 47:1158.
12. Hellewell SB and Bowen WD (1990) A sigma-like binding site in rat pheochromocytoma (PC12) cells: decreased affinity for (+)-benzomorphans and lower molecular weight suggest a different sigma receptor form from that of guinea pig brain. Brain Res 527:244-253.
13. Hellewell SB, Bruce A, Feinstein G, Orringer J, Williams W, and Bowen WD (1994) Rat liver and kidney contain high densities of sigma 1 and sigma 2 receptors: characterization by ligand binding and photoaffinity labeling. Eur J Pharmacol 268:9-18.
14. John CS, Bowen WD, Saga T, Kinuya S, Vilner BJ, Baumgold J, Paik CH, Reba RC, Neumann RD, Varma VM, et al. (1993) A malignant melanoma imaging agent: synthesis, characterization, in vitro binding and biodistribution of iodine-125-(2-piperidinylaminoethyl)4-iodobenzamide. J Nucl Med 34:2169-2175.
15. John CS, Vilner BJ, Schwartz AM, and Bowen WD (1996) Characterization of sigma receptor binding sites in human biopsied solid breast tumors. J Nucl Med 37:267P.
16. Kaushal N, Robson MJ, Vinnakota H, Narayanan S, Avery BA, McCurdy CR, and Matsumoto RR (2011) Synthesis and pharmacological evaluation of 6-acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79), a cocaine antagonist, in rodents. AAPS J 13:336-346.
17. Kaushal N, Seminerio MJ, Robson MJ, McCurdy CR, and Matsumoto RR (2013) Pharmacological evaluation of SN79, a sigma (s) receptor ligand, against methamphetamine-induced neurotoxicity in vivo. Eur Neuropsychopharmacol 23:960-971.
18. Mach RH, Smith CR, Al-Nabulsi I, Whirrett BR, Childers SR, and Wheeler KT (1997) Sigma-2 receptors as potential biomarkers of proliferation in breast cancer. Cancer Res 57:156-161.
19. Mach RH, Zeng C, and Hawkins WG (2013) The s2 receptor: a novel protein for the imaging and treatment of cancer. J Med Chem 56:7137-7160.
20. Maurice T and Su TP (2009) The pharmacology of sigma-1 receptors. Pharmacol Ther 124:195-206.
21. McCurdy CR, Mesangeau C, Matsumoto RR, Poupaert JH, Avery BA, and Abdelazeem AHA (2014) inventors, University of Mississippi, assignee. Highly selective sigma receptor ligands. U.S. Patent US 8686008 B2. 2014 Apr 1.
22. Nordenberg J, Perlmutter I, Lavie G, Beery E, Uziel O, Morgenstern C, Fenig E, and Weizman A (2005) Anti-proliferative activity of haloperidol in B16 mouse and human SK-MEL-28 melanoma cell lines. Int J Oncol 27:1097-1103.
23. Ostenfeld MS, Fehrenbacher N, HØyer-Hansen M, Thomsen C, Farkas T, and Jäättelä M (2005) Effective tumor cell death by sigma-2 receptor ligand siramesine involves lysosomal leakage and oxidative stress. Cancer Res 65: 8975-8983.
24. Vilner BJ and Bowen WD (2000) Modulation of cellular calcium by sigma-2 receptors: release from intracellular stores in human SK-N-SH neuroblastoma cells. J Pharmacol Exp Ther 292:900-911.
25. Vilner BJ, de Costa BR, and Bowen WD (1995a) Cytotoxic effects of sigma ligands: sigma receptor-mediated alterations in cellular morphology and viability. J Neurosci 15:117-134.
26. Vilner BJ, John CS, and Bowen WD (1995b) Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res 55: 408-413.
27. Wang X and Bowen WD (2006) Sigma-2 receptors mediate apoptosis in SK-N-SH neuroblastoma cells via caspase-10-dependent Bid cleavage and mitochondrial release of endonuclease G and apoptosis-inducing factor. Neuroscience 2006; 2006 Oct 14-18; Atlanta, GA.
28. Wheeler KT, Wang LM, Wallen CA, Childers SR, Cline JM, Keng PC, and Mach RH (2000) Sigma-2 receptors as a biomarker of proliferation in solid tumours. Br J Cancer 82:1223-1232.
29. Xu J, Zeng C, Chu W, Pan F, Rothfuss JM, Zhang F, Tu Z, Zhou D, Zeng D, Vangveravong S, et al. (2011) Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site. Nat Commun 2:380 10.1038/ncomms1386.
30. Zeng C, Rothfuss J, Zhang J, Chu W, Vangveravong S, Tu Z, Pan F, Chang KC, Hotchkiss R, and Mach RH (2012) Sigma-2 ligands induce tumour cell death by multiple signalling pathways. Br J Cancer 106:693-701.
31. Zeng C, Rothfuss JM, Zhang J, Vangveravong S, Chu W, Li S, Tu Z, Xu J, and Mach RH (2014) Functional assays to define agonists and antagonists of the sigma-2 receptor. Anal Biochem 448:68-74.